A Phase 2 interventional study of Cetuximab and 5-fluorouracil in Rectal Cancer, sponsored by US Oncology Research. Completed at 41 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-03.
Sponsored by US Oncology Research (part of Sarah Cannon Research Institute) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing cetuximab in Rectal Neoplasms — 4 open to participants now, 8 under way, 3 of them phase 3. Cetuximab · Rectal Neoplasms.
Among the 60 studies testing cetuximab in Rectal Neoplasms, this one is the 13th largest by enrollment of the 58 interventional ones that give a count, is one of 12 that started in 2007, is one of 38 in phase 2, and was the 28th registered.
2,403 studies on the registry are indexed under Rectal Neoplasms; 589 are open to participants now.
Browse Rectal Neoplasms studies →4 of the 60 studies testing cetuximab in Rectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Sixth Affiliated Hospital, Sun Yat-sen University · Sites in China
Ages 18–75
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 26 more countries
Ages 18+
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Ages 18–75
Tang-Du Hospital
Ages 18–70
By country, each count listing its studies:
Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 405 Rectal Neoplasms studies recruiting now, 210 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 43 · Phase 3 9
First in 1999; this study’s year is marked. 12 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 139 is above the median of 65 across 1,753 interventional studies indexed under Rectal Neoplasms.
Median enrollment 50 across the 58 interventional studies. Of the 40 that completed or were terminated, 17 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under US Oncology Research, one of the names counted as Sarah Cannon Research Institute. Under that name alone:
US Oncology Research is the lead sponsor of 29 studies on the registry; 1 is open to participants now.
Sarah Cannon Research Institute has 2 studies filed under Rectal Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies testing cetuximab in Rectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059949Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyShort Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer | 2027-01-30 |
Add it to your calendar (.ics) → With an account.
Among the 60 studies testing cetuximab in Rectal Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to find out what effects (good and bad) cetuximab has on rectal cancer.
Rectal cancer remains a significant cause of morbidity and mortality in the United States. Standard treatment for patients with locally advanced rectal cancer generally includes combined chemotherapy and radiotherapy administered either before (neoadjuvant) or after (adjuvant) definitive surgical resection. Published data from Germany has suggested advantages to a neoadjuvant strategy. Currently, the standard concurrent chemoradiotherapy regimen in the United States is pelvic irradiation administered concurrently with 5-fluorouracil (5-FU) given as a protracted venous infusion. However, local recurrence remains a problem. Recently completed randomized trials of chemoradiotherapy have demonstrated local recurrence rates between 8-17% even with currently accepted standard chemoradiotherapy and adequate surgical management.
Several recent trials have explored the use of radiotherapy and cetuximab with good results.
Because of the non-overlapping toxicity profiles and the potentially diverse and complimentary mechanisms of action, the combination of chemotherapy plus ERBITUX given concurrently with pelvic radiotherapy may improve on the outcomes seen with current standards for patients with locally advanced adenocarcinoma of the rectum.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Note: Please see Section 8.1 for the necessary "Prestudy Assessments".
A patient will be eligible for inclusion in this study if s/he meets all of the following criteria:
White blood cell (WBC) count See protocol for specific details (ANC) See protocol for specific details See protocol for specific details Total See protocol for specific details and ALT See protocol for specific details Serum creatinine See protocol for specific details count See protocol for specific details
Prior to study enrollment, women of childbearing potential (WOCBP) must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy. In addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control.
All WOCBP MUST have a negative pregnancy test within 3 weeks prior to registration (confirmed within 7 days prior to first receiving product). If the pregnancy test is positive, the patient must not receive investigational product and must not be enrolled in the study.
In addition, all WOCBP should be instructed to contact the Investigator immediately if they suspect they might be pregnant (eg, missed or late menstrual period) at any time during study participation.
The Investigator must immediately notify BMS in the event of a confirmed pregnancy in a patient participating in the study.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pelvic irradiation plus 5-fluorouracil plus cetuximab
Drug: Cetuximab · Drug: 5-fluorouracil · Radiation: Pelvic irradiation
Pelvic irradiation plus 5-fluorouracil
Drug: 5-fluorouracil · Radiation: Pelvic irradiation
Also known as: Erbitux
Also known as: 5-FU
Also known as: Radiotherapy
Percentage of Pathologic Response Rate (pCR) With 95% Confidence Interval.
A pathologic complete response (pCR) is defined as no pathologic evidence of invasive disease at the primary site in the bowel wall or in examined mesorectal tissue and/or lymph nodes.
Time frame: 5 years
To Determine Objective Response Rate (ORR) Based on RECIST Local Recurrence-free Survival in These Patient Groups; Overall and Recurrence-free Survival in These Cohorts.
Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.
Time frame: 5 years
5- Year Overall Survival (OS) Rate
Overall survival is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the date of last contact.
Time frame: 5 years
Recurrence-free Survival (RFS) Rate at 5 Years
RFS is measured from the date of randomization to the date of first documented disease recurrence or date of death, whichever comes first. If a patient neither recurrences nor dies, this patient will be censored at the date of last contact.
Time frame: 5 years
KRAS Mutation Rate
Percentage of Participants with KRAS mutation.
Time frame: 5 years
| Milestone | Chemoradiotherapy Plus Cetuximab | Chemoradiotherapy Alone |
|---|---|---|
| Started | 70 | 69 |
| Completed | 50 | 47 |
| Not completed | 20 | 22 |
| Withdrew: Adverse event | 14 | 13 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Investigator request | 2 | 1 |
| Withdrew: Patient request | 2 | 5 |
| Withdrew: Other | 2 | 2 |
A pathologic complete response (pCR) is defined as no pathologic evidence of invasive disease at the primary site in the bowel wall or in examined mesorectal tissue and/or lymph nodes.
| percentage of participants | Chemoradiotherapy Plus Cetuximab | Chemoradiotherapy Alone |
|---|---|---|
| Percentage of Pathologic Response Rate (pCR) With 95% Confidence Interval. | 26.6 (16.3 to 39.1) | 26.7 (16.1 to 39.7) |
Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.
| percentage of participants | Chemoradiotherapy Plus Cetuximab | Chemoradiotherapy Alone |
|---|---|---|
| To Determine Objective Response Rate (ORR) Based on RECIST Local Recurrence-free Survival in These Patient Groups; Overall and Recurrence-free Survival in These Cohorts. | 52.2 (39.7 to 64.6) | 43.5 (31.0 to 56.7) |
Overall survival is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the date of last contact.
| probability of overall survival | Chemoradiotherapy Plus Cetuximab | Chemoradiotherapy Alone |
|---|---|---|
| 5- Year Overall Survival (OS) Rate | 0.81 (0.69 to 0.89) | 0.68 (0.53 to 0.79) |
RFS is measured from the date of randomization to the date of first documented disease recurrence or date of death, whichever comes first. If a patient neither recurrences nor dies, this patient will be censored at the date of last contact.
| probability of recurrence-free survival | Chemoradiotherapy Plus Cetuximab | Chemoradiotherapy Alone |
|---|---|---|
| Recurrence-free Survival (RFS) Rate at 5 Years | 0.65 (0.51 to 0.76) | 0.585 (0.44 to 0.71) |
Percentage of Participants with KRAS mutation.
| percentage of participants with mutation | Chemoradiotherapy Plus Cetuximab | Chemoradiotherapy Alone |
|---|---|---|
| KRAS Mutation Rate | 32.5 | 44.0 |
Collected over During the whole treatment period, up to 30 days following last dose.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Chemoradiotherapy Plus Cetuximab | — | 10/67 (14.9%) | 61/67 (91%) |
| Chemoradiotherapy Alone | — | 5/62 (8.1%) | 47/62 (75.8%) |
| Event | Chemoradiotherapy Plus Cetuximab | Chemoradiotherapy Alone |
|---|---|---|
| DEHYDRATIONGastrointestinal disorders | 5/67 | 2/62 |
| DIARRHEAGastrointestinal disorders | 5/67 | 1/62 |
| MUCOSITISInfections and infestations | 1/67 | 2/62 |
| SEPSISInfections and infestations | 2/67 | 0/62 |
| ABDOMINAL PAINGastrointestinal disorders | 1/67 | 1/62 |
| ENTERITISGastrointestinal disorders | 0/67 | 1/62 |
| SWALLOWING PAINFULGastrointestinal disorders | 0/67 | 1/62 |
| WEAKNESS GENERALIZEDGeneral disorders | 0/67 | 1/62 |
| COLITISGastrointestinal disorders | 1/67 | 0/62 |
| FEVERGeneral disorders | 1/67 | 0/62 |
| Event | Chemoradiotherapy Plus Cetuximab | Chemoradiotherapy Alone |
|---|---|---|
| RASHSkin and subcutaneous tissue disorders | 50/67 | 5/62 |
| DIARRHEAGastrointestinal disorders | 36/67 | 33/62 |
| WEAKNESSGeneral disorders | 25/67 | 19/62 |
| MUCOSITISInfections and infestations | 19/67 | 12/62 |
| NAUSEAGastrointestinal disorders | 18/67 | 13/62 |
| ANOREXIAGastrointestinal disorders | 16/67 | 13/62 |
| HEADACHEGeneral disorders | 13/67 | 1/62 |
| HYPOMAGNESAEMIAMetabolism and nutrition disorders | 10/67 | 4/62 |
| HAND-FOOT SYNDROMESkin and subcutaneous tissue disorders | 2/67 | 9/62 |
| ABDOMINAL PAINGastrointestinal disorders | 5/67 | 8/62 |
ITT population
| Age, Continuous(years) | Chemoradiotherapy Plus Cetuximab | Chemoradiotherapy Alone | Total |
|---|---|---|---|
| Mean | 55.9 ± 11.0 | 61.4 ± 11.7 | 58.6 ± 11.3 |
| Sex: Female, Male(Participants) | Chemoradiotherapy Plus Cetuximab | Chemoradiotherapy Alone | Total |
|---|---|---|---|
| Female | 26 | 21 | 47 |
| Male | 44 | 48 | 92 |
| Race/Ethnicity, Customized(participants) | Chemoradiotherapy Plus Cetuximab | Chemoradiotherapy Alone | Total |
|---|---|---|---|
| Caucasian | 59 | 60 | 119 |
| Black | 8 | 4 | 12 |
| Hispanic | 1 | 3 | 4 |
| Asian | 2 | 1 | 3 |
| Other | 0 | 1 | 1 |
| Region of Enrollment(participants) | Chemoradiotherapy Plus Cetuximab | Chemoradiotherapy Alone | Total |
|---|---|---|---|
| United States | 70 | 69 | 139 |
The record gives a start of Feb 2007, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cetuximab